According to the American Diabetes Association, 7% of the general population and 21% of people over the age of 60 are afflicted with diabetes in the US. One of the most outward and debilitating complications of diabetes is the development of chronic non-healing foot ulcerations, occurring in 15% of diabetics. In its most unfavorable course, diabetic foot ulceration (DFU) leads to amputation in 14-24% of afflicted individuals and is the leading cause of non-traumatic lower-extremity amputation in the US.
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The national economic burden of DFU and amputation is correspondingly staggering, estimated near US$11 billion in 2001. 2 Traditionally, ischemia, neuropathy, trauma, and infection were considered the culprits of the recurring chronic wound. 3, 4 More recently, diabetic impairment of the cutaneous wound-healing process has been recognized as a major contributor to the failure to heal, and wound healing has been appreciated as yet another biological system hindered by the metabolic, vascular, neurological, and inflammatory alterations present in both type 1 and type 2 diabetes.
Wound Healing in Diabetes
Wound healing requires the well-orchestrated integration of the complex biological and molecular events of cell migration, cell proliferation, and extracellular matrix (ECM) deposition. 5 Normal wound healing can be divided into four overlapping phases: hemostasis, inflammation, proliferation, and remodeling. The cell types involved in each phase mediate specific events that culminate in wound closure. The first observations regarding the impact of diabetes on wound healing focused on an impaired leukocyte function related to hyperglycemia. 6, 7 However, additional factors common to other chronic wounds, such as decubitus ulcers and venous ulcers, were later found to participate in impaired diabetic wound healing. 8 These abnormalities included the development of pericapillary fibrin cuffs, 9 impaired expression of ECM, 10 aberrant cellular infiltration, 11 insufficient macrophage activation, 12 impaired re-epithelialization, and impaired angiogenesis.
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Current Therapies
Diabetic ulcers are classified as ischemic or neuropathic, and treatment relies upon the proper identification of ulcer type. 15 Ischemic ulcers are painful ulcers of the toes that appear in the setting of severe arterial insufficiency with diminished distal pulses. The primary impairment leading to ulceration is large-vessel occlusion, and prompt surgical revascularization is indicated. 16, 17 Neuropathic ulcers are painless ulcers that appear on the edges or the sole of the foot in the setting of adequate distal blood flow. These ulcers result from sensory and autonomic neuropathy and current principles of treatment include debridement, pressure off-loading, infection control, judicious wound care, tight glycemic control, and optimization of cholesterol, nutrition, and other lifestyle factors. 15, 18 Impaired diabetic wound healing impedes the healing process in both instances, and additional adjunctive measures are often undertaken to assist in ulcer healing.
Bioengineering and Technology
Bioengineering and technological advances have led to the development of artificial skin grafts, matrix wound dressings, and vacuum-assisted closure devices for the promotion of wound healing. 
Surgery
Achilles tendon lengthening has been shown to be an effective strategy for promoting diabetic ulcer healing and preventing ulcer recurrence in patients with equinus deformity of the foot and limited dorsiflexion. 29, 30 Poor dorsiflexion leads to increased plantar pressures that contribute to ulcer formation by causing painless trauma and skin breakdown in the setting of the insensate neuropathic foot. The percutaneous lengthening procedure can be performed under local anesthesia and consists of three hemisections of the Achilles tendon. Afterwards, the foot is placed in a total-contact cast for six weeks to allow for healing of the primary ulcer. Following ulcer resolution, significant reductions in ulcer recurrence as high as 75% after two years were shown in a randomized controlled trial comparing Achilles tendon lengthening to casting alone. 30 Biomechanical studies have demonstrated the procedure serves to off-load the foot by increasing ankle dorsiflexion with a subsequent decrease in peak forefoot pressures.
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Non-surgical Debridement
Maggots were used extensively in the 1930s for the debridement of wounds. Use of maggots declined with the advent of modern antibiotics and surgical debridement techniques, but experienced a resurgence in the 1990s after a study by Sherman and colleagues reaffirmed their utility. 32 The larvae of the blowfly, Lucilia sericata, are the most frequently used species for wound treatment as they are found to feed only on necrotic tissue. 33 Different mechanisms of wound healing by maggots have been suggested, including: 34 • liquefaction of necrotic tissue by secretion of proteolytic enzymes;
• ingestion of necrotic tissue;
• mechanical irrigation of bacteria by the serous exudate produced by the irritating effect of maggots in the wound;
• destruction of bacteria in the alimentary tract of the maggots or by antibacterial secretions;
• alkalinization of the wound as a result of ammonia and calcium carbonate secretion;
• secretion of substances with wound-healing properties such as allantoin and urea; and
• promotion of granulation tissue by mechanical stimulation of viable tissue by the continuous crawling of the larvae.
Maggot therapy has been shown to reduce the time for wound healing in diabetic patients along with reducing the incidence of infection, but is understandably reserved for when other conventional therapies and surgical interventions have failed.
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Future Therapies
Growth Factors
Growth factors are released from platelets, macrophages, neutrophils, In a diabetic mouse study, PDGF lentiviral vectors were successfully transfected into the regenerating dermis of diabetic wounds. Although re-epithelialization was similar among the groups, there was enhanced angiogenesis and collagen deposition in the lentiviral PDGF group. 64 In a similar study, quantitative analysis showed a 3.5-fold and 2.3-fold increase in collagen content in lentiviral PDGF-treated wounds versus untreated and saline-treated wounds, respectively. 65 In another diabetic mouse study, a plasmid expressing TGF-beta-1 was injected in the wound bed followed by 
Cell-based Therapies
Cell therapy is emerging as an exciting modality for promoting wound healing. Numerous studies have investigated the potential of stem cells, keratinocytes, and fibroblasts for the treatment of chronic wounds.
However, few studies have explored these strategies in diabetics, and to date only fibroblasts have been used for the treatment of diabetic ulcers. 
